Engineered LINE Transposons for Targeted Genome Editing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current genome editing technologies face limitations such as low frequency of editing events and high off-target effects, which hinder their clinical application in treating diseases like cancer and genetic disorders.
Innovation Solution
Engineered transposons comprising an RNA component with a DNA targeting sequence and a protein component derived from RLE LINE elements, which facilitate targeted integration of a nucleic acid sequence of interest into the genome, utilizing mechanisms like target primed reverse transcription to enhance specificity and efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If CRISPR-Cas9 is used for genome editing, then gene editing capability is achieved, but editing frequency is low and off-target events are high
Solution Approach 1:
The transposon system is divided into separate components: a DNA component containing the gene of interest flanked by inverted terminal repeats, and a separate transposase enzyme. This segmentation allows the DNA to be delivered and integrated without the Cas9 protein that causes off-target effects, while the transposase provides site-specific integration capability.
Solution Approach 2:
The patent uses an RNA intermediary (guide RNA) that directs the transposase to the target genomic location. This RNA mediator enables specific targeting without requiring the CRISPR-Cas9 complex, thereby achieving specific gene editing with reduced off-target effects.
2Productivity
If CRISPR-Cas9 is used for genome editing, then gene editing capability is achieved, but editing frequency is low
Solution Approach 1:
The patent changes the fundamental mechanism from Cas9-mediated double-strand break to transposase-mediated transposition. This parameter change in the editing mechanism increases editing frequency by utilizing the natural high-efficiency integration capability of transposons while maintaining targeting specificity through guide RNA.
3Manufacturing precision
If transposons are engineered for targeted integration, then integration specificity is improved, but system complexity increases
Solution Approach 1:
The patent extracts the essential functions needed for targeted integration (guide RNA for targeting, transposase for integration) and removes unnecessary components from the CRISPR system (Cas9 protein, complex gRNA structure). This simplification maintains integration specificity while reducing system complexity.
Solution Approach 2:
The transposase enzyme performs multiple functions: it binds to the guide RNA, recognizes the target site, and catalyzes the integration of the DNA payload. This multi-functionality reduces the need for separate components, thereby simplifying the overall system while maintaining precise integration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered transposons improve the frequency and specificity of gene editing events, potentially leading to more effective therapeutic interventions for diseases by enabling precise modification of genomic DNA.
Implementation Method 1
The RNA segments involved in binding to protein, the protein binding motifs (PBM), typically bind to an RNA binding domain (domain −1), a reverse transcriptase, a linker domain, an endonuclease, or a combination thereof of the protein component
Implementation Method 2
the resulting cDNA can be integrated into the DNA at the DNA target site... facilitate reverse transcription of the RNA component into cDNA
Implementation Method 3
an endonuclease... facilitate reverse transcription of the RNA component into cDNA, and integration of the cDNA into the DNA at the DNA target site
Implementation Method 4
utilizing mechanisms like target primed reverse transcription to enhance specificity and efficiency
Data Source
AI summary
Engineered transposons and methods of use thereof are provided. The transposons typically include an RNA component and a protein component. The RNA component can include, for example, a DNA targeting sequence, one or more protein binding motifs, and a nucleic acid sequence of interest to be integrated into a target DNA. The protein component is typically derived from a RLE LINE element protein and can include a DNA binding domain, an RNA binding domain, a reverse transcriptase, a linker domain, and an endonuclease. Pharmaceutical compositions and methods of use for introducing nucleic acid sequences into the genomes of cells are also provided.